Immune response in prostate cancer

Minerva Urologica e Nefrologica

Volumn 57, Issue 4, 2005, Pages 301-311

  Cracco, C M ^a   Terrone, C ^a   Porpiglia, F ^a   Scarpa, R M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Immune system; Immunotherapy; Prostatic neoplasms

Indexed keywords

ANDROGEN; B7 ANTIGEN; BASILIXIMAB; CANCER VACCINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HYDROCORTISONE; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; NEUROTRANSMITTER; NEUROTROPHIN; OXYTOCIN; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CANCER PATIENT; CANCER SURGERY; CANCER THERAPY; CIGARETTE SMOKING; DIET; GENE; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY INFILTRATE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROPHYLAXIS; PROSTATE CANCER; REVIEW; TUMOR CELL; TUMOR IMMUNITY; VACCINATION;

CYTOKINES; GONADAL STEROID HORMONES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 28544453176     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2:389-6.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
3. Fontana G, Pugliese A. The immune response to cryotherapy of prostatic carcinoma. G Batteriol Virol Immunol 1975;68:301-4.
4. Polledro P, Ambruoso G, Governa M, Fontana G. Carcinoma prostatico in stadio localmente avanzato, svincolato dalla terapia ormonale: trattamento con interferone beta per via intralesionale. In: Corrado F, Maltoni C, Corrado G, Ferri C, Palazzini A, Pinto C, editors. I tumori urologici: recenti progressi e nuovi obiettivi della ricerca. Bologna: Monduzzi Editore; 1992.p.935-7.
5. Sarosdy MF. Oral bropirimine immunotherapy of rodent prostate cancer. Eur Urol 1997;31 Suppl:5-9.
6. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 2000;164:1825-9.
7. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J et al. Recombinant prostatic specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003;56:212-9.
8. Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H et al. Inhibition of dendropoiesis by tumor-derived and purified prostate specific antigen. J Urol 2003;170:2026-30.
9. Yao G, Liang J, Han X, Hou Y. In vivo modulation of the circulating lymphocyte subsets and monocytes by androgen. Int Immunopharmacol 2003;3:1853-60.
10. Zheng R, Samy ATS, Schneider CP, Rue LW 3rd, Bland KI, Chaudry IH. Decreased 5alpha-dihydrotestosterone catabolism suppresses T lymphocyte functions in males after trauma-hemorrhage. Am J Physiol Cell Physiol 2002;282:C1332-C8.
11. Posma E, Moes H, Heineman MJ, Faas MM. The effect of testosterone on cytokine production in the specific and non-specific immune response. Am J Reprod Immunol 2004;52:237-43.
12. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004;173:6098-108.
13. Bonkhoff H. Morphogenesis of prostate cancer. In: Sell S editor. Stem cells handbook. Totowa, NJ: Humana Press Inc.; 2004.p.445-53.
14. Schaltzl G, Reiter WJ, Thurridl T, Waldmuller J, Roden M, Soregi S et al. Endocrine patterns in patients with benign and malignant prostatic diseases. Prostate 2000;44:219-24.
15. Suarez C, Garcia Tornadu I, Khalil W, Becu-Villalobos D. Dehydroepiandrosterone treatment attenuates oestrogen-induced pituitary hyperplasia. J Endocrinol 2002;174:447-54.
16. Simard J, Gingras S. Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Mol Cell Endocrinol 2001;171:25-40.
17. Whittington K, Assinder S, Gould M, Nicholson H. Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. Cell Tissue Res 2004;318:375-82.
18. Cassoni P, Marrocco T, Sapino A, Allia E, Bussolati G. Evidence of oxytocin/oxytocin receptor interplay in human prostate gland and carcinomas. Int J Oncol 2004;25:899-904.
19. Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells. Ann N Y Acad Sci 2000;917:505-13.
20. Matera L, Mori M, Galetto A. Effect of prolactin on antigen presenting function of monocyte-derived dendritic cells. Lupus 2001;10:728-34.
21. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49.
22. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I et al. Boosting antitumor responses by T lymphocytes infiltrating human prostate cancers. J Exp Med 2005;201:1257-68.
23. Fontana G, Cracco C. Immunoterapia nei tumori urologici. In: Mazzeo F editor. Trattato di clinica e terapia chirurgica. Padova: Piccin; 2003. vol. III, p. 4277-83.
24. Furbert-Harris P, Parish-Gause D, Laniyan I, Hunter KA, Okomo-Awich J, Vaughn TR et al. Inhibition of prostate cancer cell growth by activated eosinophils. Prostate 2003;57:165-75.
25. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000;60:5857-61.
26. Herwig R, Horniger W, Rehder P, Ramoner R, Thurnher M, Pinggera GM et al. Ability of PSA-positive circulating macrophages to detect prostate cancer. Prostate 2005;62:290-8.
27. Herwig R, Pelzer A, Horninger W, Rehder P, Klocker H, Ramoner R et al. Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. Clin Prostate Cancer 2004;3:184-8.
28. Saito K, Takeha S, Shiba K, Matsuno S, Sorsa T, Natura H et al. Clinicopathological significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis. Int J Cancer 2000;86:24-9.
29. Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol Rep 2004;11:1187-92.
30. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 2003;144:1656-63.
31. Hanahan D, Lanzavecchia A, Mihic E. The novel dichotomy of immune interactions with tumors. Cancer Res 2003;63:3005-8.
32. Yang G, Addai J, Tian W, Frolov A, Wheeler TM, Thompson TC. Reduced infiltration of class A scavanger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res 2004;64:2076-82.
33. Wang W, Bergh A, Damber JE. Cycloxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005;11:3250-6.
34. Karin M, Cao Y, Greten FR, Li Z. NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
35. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI et al. Nuclear factor-kappa B/p65 (RelA) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004;6:390-400.
36. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002;2:537-43.
37. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000;164:722-5.
38. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA et al. EGF and hypoxia-induced expression of CXCR4 on NSCLC cells is regulated by the PI3-kinase/PTEN/AKT/mTOR signalling pathway and activation of HIF-1alpha. J Biol Chem 2005;280:22473-81.
39. Sun YX, Schneider A, Jang Y, Wang J, Dai J, Wang J et al. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks metastasis and growth in osseous sites in vivo. J Bone Mineral Res 2005;20:318-29.
40. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004;84:1666-76.
41. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6 and cyclic AMP-mediated signalling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001;21:8471-2.
42. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Corey E. Elevation of cytokine levels in cachectic patients with prostate cancer. Cancer 2003;97:1211-6.
43. Garcia-Moreno C, Mendez-Davila C, de la Pietra C, Castro-Errecaborde NA, Traba ML. Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 2002;50:241-6.
44. Akakura K, Suzuki H, Ueda T, Komiya A, Ichigawa T, Igarashi T et al. Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin 6. Prostate 2003;56:106-9.
45. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 2004;91:541-3.
46. Schwemmer B. Natural killer T cells in patients with prostatic carcinoma. Urol Int 2003;71:146-9.
47. Pirtskhalaishvili G, Shurin GV, Esche C, Trump DL, Shurin MR. TNF-alpha protects dendritic cells from prostate cancer-induced apoptosis. Prostate Cancer Prostatic Dis 2001;4:221-7.
48. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000;164:800-5.
49. Davis JN, Kucuk O, Djuric Z, Sarkar FH. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 2001;30:1293-302.
50. Fujiuchi Y, Nagakawa O, Murakami K, Fuse H, Saiki I. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol Rep 2003;10:1001-6.
51. Cracco C, Terrone C, Poggio M, Tarabuzzi R, Scoffone C, Porpiglia F et al. Met, the HGF receptor: possible role in prostatic cancer metastatization. Eur Urol 2005;48 Suppl 4:24.
52. Galimi F, Cottone E, Vigna E, Arena N, Boccaccia C, Giordano S et al. Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol 2001;166:1241-7.
53. Harris AL. Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2002;2:38-47.
54. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signalling increases the rate of the hypoxia-inducible factor 1alpha (HIF-1 alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
55. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve- an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000;52:595-638.
56. Wang H, Yu M, Ochani M, Amelia CA, Tanovic M, Susarla S et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-8.
57. Emanueli C, Schratzberger P, Kirchmair R, Madeddu P. Paracrine control of vascularization and neurogenesis by neurotrophins. Br J Pharmacol 2003;140:614-9.
58. Sigala S, Tognazzi N, Rizzetti MC, Faraoni I, Missale C, Bonmassar E et al. Nerve growth factor induces the re-expression of functional androgen receptors and p75 (NGFR) in the androgen-insensitive prostate cancer cell line DU145. Eur J Endocrinol 2002;147:407-15.
59. Satoh F, Minata H, Nomura T, Fujita Y, Shin T, Sakamoto S et al. Autocrine expression of neurotrophins and their receptors in prostate cancer. Int J Urol 2001;8:S28-34.
60. Krygier S, Djakiew D. Neurotrophin receptor p75 (NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 2002;98:1-7.
61. Berruti A, Dogliotti L, Mosca A, Tarabuzzi R, Torta M, Mari M et al. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer. Prostate 2001;47:205-11.
62. Zukowska Z, Pons J, Lee EW, Li L. Neuropeptide Y. a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 2003;81:89-94.
63. De la Fuente M, Del Rio M, Victor VM, Medina S. Neuropeptide Y effects on murine natural killer activity: changes with ageing and cAMP involvement. Regul Pept 2001;101:73-9.
64. Magni P, Motta M. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 2001;12 Suppl 2:S27-9.
65. Libert C. A nervous connection. Nature 2003;421:328-9.
66. Roberts WW, Platz EA, Walsh PC. Association of cigarette smoking with extraprostatic prostate cancer in young men. J Urol 2003;169:512-6.
67. Ames BN, Wakimoto P. Are vitamin and mineral deficiencies a major cancer risk? Nat Rev Cancer 2002;2:694-704.
68. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000;164:800-5.
69. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 2005;135:989-95.
70. Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2 and cell invasion in human prostate epithelial cells. Cancer Res 2005;65:3470-8.
71. Slade MS, Simons RL, Yunis E, Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery 1975;79:363-7.
72. Boehm M, Allhoff EP. Immunodysfunction and surgery. Enhancer Biother Cancer 2004;2:15-8.
73. Milleman LA, Weissman WD, Culp DA. Serum protein, enzyme and immunoglobulin responses following perineal cryosurgery for carcinoma of the prostate. J Urol 1980;123:710-1.
74. Kramer G, Steiner GE, Grobl M, Hrachowitz K, Reithmayr F, Paucz L et al. Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cells. Prostate 2004;58:109-20.
75. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003;10:823-32.
76. Pandha H, Eaton J, Greenhalgh R, Soars D, Dalgleish A. Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy. Cancer Gene Ther 2005;12:572-8.
77. Dalgliesh A, Whelan M. Novel immunotherapeutic approaches to prostate cancer. Curr Opin Mol Ther 2005;7:30-4.
78. Belldegrun A, Bander NH, Lerner SP, Wood DP, Pantuck AJ. Society of urologic oncology biotechnology forum: new approaches and targets for advanced prostate cancer. J Urol 2001;166:1316-21.
79. Fitzpatrick JM. New developments in the pharmacological management of prostate cancer. BJU Int 2000;85 Suppl 2:31-7.
80. Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG. Gene therapy for prostate cancer: current status and future prospects. J Urol 2001;166:1220-33.
81. Satoh T, Irie A, Egawa S, Baba S. In situ gene therapy for prostate cancer. Curr Gene Ther 2005;5:111-9.
82. Tien AH, Xu L, Helgason CD. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res 2005;65:2947-55.
83. Morris MJ, Reuter VE, Kelly KW, Slovin SF, Kenneson K, Verbel D et al. HER-2 profiling and targeting in prostate carcinoma. A phase II trial of trastuzumab alone and with paclitaxel. Cancer 2002;94:980-6.
84. Caglià A, Valabrega G, Cracco C, Sottili A, Guercio S, Poggio M et al. Erb-B2: a target for prostate cancer therapy? Eur Urol Suppl 2004;3:116.
85. Lum HE, Miller M, Davol PA, Grabert RC, Davis JB, Lum LG. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas. Anticancer Res 2005;25:43-52.
86. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-309.
87. Schellhammer PF, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 2005;23:47-9.
88. Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005;62:217-23.